<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew R Freedman, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Robertson, MRCP, FRCPath</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human T-lymphotropic virus (HTLV-I), the first human retrovirus to be discovered [<a href="#rid1">1</a>], is estimated to infect 5 to 10 million people worldwide [<a href="#rid2">2,3</a>]. This virus is considered the most oncogenic human pathogen [<a href="#rid4">4</a>] and is the causative agent of two typically fatal diseases: adult T cell leukemia-lymphoma (ATL) [<a href="#rid5">5-7</a>] and HTLV-I-associated myelopathy [<a href="#rid8">8</a>], which is also known as tropical spastic paraparesis [<a href="#rid9">9</a>].</p><p>The epidemiology, virology, and pathogenic features of HTLV-I will be reviewed here. The diagnosis, disease associations, and treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">VIROLOGY</span><span class="headingEndMark"> — </span>HTLV-I is an enveloped, single-stranded RNA virus of the <em>Retroviridae</em> family, the only human pathogen of the subfamily oncovirus, which includes HTLV-II, bovine leukemia virus, simian T cell leukemia virus, HTLV-III, and HTLV-IV [<a href="#rid10">10</a>]. It has a diploid genome, comprised of two identical strands of positive sense RNA, each 9032 base pairs long. The genomic organization is similar to other retroviruses, with two long terminal repeat (LTR) sequences flanking gag, pol, and env genes  (<a class="graphic graphic_figure graphicRef61279" href="/z/d/graphic/61279.html" rel="external">figure 1</a>).</p><p>However, HTLV-I also possesses a unique 1.6 kb region, termed pX, which is located between env and the 3'LTR [<a href="#rid11">11</a>]. This region encodes a number of regulatory proteins: p40tax (Tax), p27rex, p21rex, p12, p13 and p30. HTLV-I basic leucine zipper factor (HBZ) is encoded by the minus (complementary) strand of pX region [<a href="#rid12">12</a>]. Of these, Tax and HBZ have been most implicated in viral pathogenesis. (See <a class="local">'Pathogenesis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Cell entry and replication</span><span class="headingEndMark"> — </span>Viremia in HTLV-I infection is of an extremely low level, in contrast to HIV infection. New infection is the result of transmission of infected lymphocytes rather than cell-free viral particles. HTLV-I displays CD4 T cell tropism, but virion entry to CD4 T cells occurs most efficiently by direct cell-to-cell contact via a virological synapse [<a href="#rid13">13</a>] rather than from virions free in plasma. Cell-free HTLV-I can also infect dendritic cells (via heparin sulphate proteoglycans and neuropilin-1) [<a href="#rid14">14</a>] and can subsequently be transmitted from dendritic cells to CD4 T cells [<a href="#rid15">15</a>]. The glucose transporter, glut-1 [<a href="#rid16">16,17</a>], has also been identified as a receptor for the HTLV-I envelope glycoprotein (env). However, cells lacking GLUT-1 expression can be infected by HTLV-I [<a href="#rid18">18</a>]. HTLV-I-infected CD4 T cells can produce CCL22, a CCR4 ligand. CCL22 attracts CCR4-expressing CD4 cells, resulting in the preferential transmission of HTLV-I to CCR4-positive, CD4-positive T cells [<a href="#rid19">19</a>].</p><p>After entering the cell, the RNA genome of HTLV-I is reverse transcribed, generating a DNA product that integrates in a non-random manner into the host genome. Following integration, viral replication can occur in two ways. First, re-expression of the integrated provirus forms a new intracellular virion (also termed "infectious" replication) [<a href="#rid20">20</a>]. Second, the integrated provirus replicates with each mitotic cell division. This results in a low viral replication rate and, given that mitotic replication is driven by host rather than by viral DNA polymerase, a high fidelity of transcription. These factors combine to explain the high genetic stability of HTLV-I [<a href="#rid21">21</a>].</p><p>HTLV-I regulates its own transcription via Tax, which acts as a transcriptional activator [<a href="#rid22">22,23</a>], and Rex, which acts to suppress transcription by regulating viral mRNA splicing. The opposing actions of Tax and Rex result in transient expression of viral gene products, which may assist in evasion of the host immune response [<a href="#rid24">24</a>]. When integrated as provirus, persistent infection is established, and subsequent translation of viral products can induce numerous cellular changes favoring cell survival and proliferation. Infection does not induce any cytopathic effect.</p><p class="headingAnchor" id="H4"><span class="h2">Proviral load determination</span><span class="headingEndMark"> — </span>There is rapid clonal expansion in the first few weeks of infection until an effective host immune response is established. After this point, most hosts carry between 10<sup>4 </sup>and 10<sup>5 </sup>different clones [<a href="#rid25">25</a>]. In asymptomatic infection, approximately 0.1 to 1 percent of peripheral blood mononuclear cells (PBMCs) carry provirus (viral DNA within the host cell genome), while higher proviral loads (up to 30 percent of PBMCs) are associated with HAM/TSP. Asymptomatic carriers with high proviral loads are more likely to progress to HAM/TSP [<a href="#rid26">26</a>]. </p><p>Proviral load is independent of age or sex [<a href="#rid27">27</a>], but varies with the natural history of the infection. A prospective study of 10 patients who acquired transfusion-related HTLV-I showed a median proviral load of 212 copies per 10<sup>5</sup> lymphocytes within three months of infection, decreasing to 27 copies per 10<sup>5</sup> lymphocytes at 14 months of infection or longer [<a href="#rid28">28</a>]. Another study examining HTLV-I viral load in 30 individuals over a median of 10.4 years found a minor decrease over time (-0.017 log copies/10<sup>6</sup> PBMCs/year) [<a href="#rid29">29</a>]. In a study of 36 asymptomatic pregnancy HTLV-1 carriers, proviral load remained stable during pregnancy but rose three-fold at one month postpartum [<a href="#rid30">30</a>]. It is unknown how long this elevation lasts.</p><p>Differences in proviral load between individuals infected with identical viral sequences suggest that host factors contribute most to proviral loads [<a href="#rid31">31</a>]. Polymorphisms in certain host MHC class I molecules have been shown to influence the proviral set-point [<a href="#rid32">32</a>], implicating antigen presentation to CD8 T cells as an important step in viral control.</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>HTLV-I shares many similarities with human immunodeficiency virus type 1 (HIV-1) but differs significantly from HIV-1 in the spectrum of diseases caused and the manner by which it causes them. Two virologic differences between HIV-1 and HTLV-I help to account for this:</p><p class="bulletIndent1"><span class="glyph">●</span>The low replication rate and the high fidelity of replication of HTLV-I result in a relatively low viral burden and high genetic stability, thereby reducing the possibility of immune escape.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HTLV-I does not induce death of T cells, but rather causes cell proliferation and transformation.</p><p></p><p>The two diseases predominantly associated with HTLV-I, ATL and HAM/TSP, rarely overlap. Further, each is associated with a different route of transmission (ATL with breast feeding, and HAM/TSP with blood transfusion), and each has different pathogenic and immunologic correlates. Overall, this suggests that HTLV-I infection can result in two fundamentally different disease processes. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Cellular transformation</span><span class="headingEndMark"> — </span>Although HTLV-I is oncogenic, it neither induces transformation by encoding oncogenes, nor does it integrate into the host genome to disrupt host gene expression. Rather, oncogenesis is mediated through viral gene products interacting with host proteins (often transcription factors), thereby altering their function. This is typified by Tax, a 40 kDa nuclear phosphoprotein. It is the molecule most associated with HTLV-I pathogenesis and has been shown to be both necessary and sufficient to induce cellular transformation [<a href="#rid33">33-36</a>].</p><p>Tax has no human homologue [<a href="#rid37">37</a>], but it is able to affect several signaling pathways, including NF-kB, CREB, SRF and AP-1 [<a href="#rid38">38</a>], in three distinct ways:</p><p class="bulletIndent1"><span class="glyph">●</span>Tax can transactivate many genes favoring T cell proliferation (including interleukin [IL]-2, IL-2Ra and IL-15), and inhibiting apoptosis (Bcl-XL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tax can trans-repress genes controlling cell cycle (p18 INK4c and lck) and DNA repair (DNA polymerase b) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tax can also bind to and functionally inactivate proteins, such as the cell cycle regulator p16INK4a, the oncosuppressor TGF-beta and the mitotic checkpoint controller MAD-1 [<a href="#rid40">40</a>].</p><p></p><p>Tax can also impair the action of the cell cycle regulator p53, although the mechanism is not fully understood. The net outcome of these effects in the infected cell is to promote cell proliferation, induce genetic instability, and inhibit apoptosis, leading to the persistent clonal expansion of infected cells and the promotion of oncogenesis.</p><p>HBZ has also been implicated in the pathogenesis of ATL and, unlike Tax, is uniformly expressed in ATL cells [<a href="#rid12">12,41</a>]. Both HBZ RNA and the protein it encodes have been shown to induce changes with the RNA altering cell proliferation and the protein suppressing Tax-mediated viral transcription. The precise mechanisms by which HBZ participates in leukemogenesis have not yet been elucidated, although its selective inhibition of cellular senescence via the classical NF-kappaB pathway [<a href="#rid42">42</a>] and ability to induce T-cell proliferation [<a href="#rid43">43</a>] may be relevant.</p><p class="headingAnchor" id="H7"><span class="h2">Immunologic control</span><span class="headingEndMark"> — </span>Both cellular and humoral responses are mounted against HTLV-I. Antibodies to gag proteins are produced within the first two months of infection, followed by antibodies specific for env proteins [<a href="#rid44">44</a>]. Anti-tax antibodies develop later in approximately half of those infected. Tax antibodies may play a role in pathogenesis of HAM/TSP, given that higher anti-Tax antibody levels are associated with higher proviral load [<a href="#rid45">45</a>] and development of HAM/TSP [<a href="#rid46">46</a>].</p><p>HTLV-specific cytotoxic T lymphocytes (CTLs) can readily be found in most HTLV-associated diseases, as well as in asymptomatic carriers, and are thought to be important in viral control. These cells primarily respond to epitopes from the Tax protein [<a href="#rid47">47,48</a>]. Mutations in Tax resulting in viral escape from CTL killing have been described [<a href="#rid49">49</a>]. Epitopes within other proteins, such as the gp46 envelope glycoprotein [<a href="#rid50">50</a>], have also been described. The significance of HTLV-specific T cells in HAM/TSP or ATL remains poorly defined. Impaired function of CTLs in both disease states has been described [<a href="#rid51">51-53</a>], although it is unclear what factors result in this functional impairment.</p><p>HTLV-I can induce a proinflammatory, type 1 T helper (Th1)-like state in CCR4-positive, CD4-positive T cells from both blood and central nervous system in patients with HAM/TSP that may play a role in pathogenesis [<a href="#rid54">54,55</a>]. Given its role in cellular transmission and immune activation, CCR4 is a promising therapeutic target in HTLV-I infection [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H8"><span class="h1">EPIDEMIOLOGY AND TRANSMISSION</span></p><p class="headingAnchor" id="H259921900"><span class="h2">Global prevalence</span><span class="headingEndMark"> — </span>HTLV-I infects an estimated 5 to 10 million people worldwide [<a href="#rid2">2,3</a>]. The true prevalence in many populous areas, such as East Africa, China, and South Asia, is currently unknown due to a lack of systematic testing. Therefore, there is substantial uncertainty surrounding any global estimate of prevalence. </p><p>HTLV-I is primarily transmitted by breast feeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs. This predominance of vertical transmission results in clustering of cases in familial or geographically discrete groups. It is endemic in southern Japan, the Caribbean, South America, the Melanesian islands, Papua New Guinea, the Middle East, and in West, Central, and Southern Africa [<a href="#rid57">57</a>]. In these endemic areas, seroprevalences range from three to five percent in Trinidad [<a href="#rid58">58</a>] up to 30 percent in rural Miyazaki in southern Japan [<a href="#rid59">59</a>].</p><p>By contrast, non-endemic areas, such as the United States and Europe, have prevalence rates of less than 1 percent [<a href="#rid60">60,61</a>]. As an example, in a study of over two million first time blood donors in the United States between 2000 and 2009, only 104 individuals (0.005 percent) were confirmed antibody positive for HTLV-I [<a href="#rid62">62</a>]. These data may underestimate the true prevalence, as potential blood donors are screened, and those with high-risk characteristics are excluded. </p><p>Seroprevalence tends to increase with age, and women are nearly twice as likely to be infected as men [<a href="#rid59">59,62,63</a>], although the sex difference is only seen after 30 years of age and probably reflects the relative efficiency of sexual transmission from male to female [<a href="#rid64">64</a>]. In Southern Japan, the seroprevalence rate among pregnant women is approximately 5 percent. This can be contrasted with much lower seropositivity in non-endemic areas in Japan (0.1 to 1 percent), a result similar to serologic studies from Europe.</p><p>HTLV-I displays little genomic variability during the course of infection or between patients in the same geographic area. Mother/child and spouse pairs from Okinawa, Japan have been shown to be infected with highly conserved, and often identical, viruses based upon direct sequencing of the viral genome [<a href="#rid21">21</a>]. Studies in France [<a href="#rid65">65</a>], Papua New Guinea, the Solomon Islands [<a href="#rid66">66</a>], and Zaire [<a href="#rid67">67</a>] have shown similarly low genomic variability based upon the less accurate sequencing of PCR products. There is recognized strain variation between geographic areas, but this variation is small.</p><p>The risk of transmission appears to be independent of HLA class 1 type, but is modestly increased by greater HLA class 1 matching between mother and child (threefold increased risk with five or six shared HLA class 1 types) [<a href="#rid68">68</a>]. Susceptibility of infection in African children has been linked to chromosome 6q27, [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Breast feeding</span><span class="headingEndMark"> — </span>HTLV-I antigen is found in the milk of infected mothers [<a href="#rid70">70</a>]; animal models have shown that breast milk alone can transmit HTLV-I [<a href="#rid71">71</a>]; and risk of infection is higher in breast-fed infants than in those who are bottle fed. Over a one-year period, breast-fed infants have a fourfold increase risk of infection (15.7 versus 3.6 percent). These findings strongly support the hypothesis that virus can be spread though breast feeding, probably through lymphocytes in milk. Overall, the risk of transmission via breast feeding is estimated to be approximately 16 to 30 percent [<a href="#rid72">72,73</a>].</p><p>A longer duration of breast feeding increases transmission risk. In a prospective study of 780 Japanese infants, those who were breast fed for seven months or more had a rate of seroconversion to HTLV-I of 14.4 percent, while those breast fed for six months or less seroconverted at an equivalent rate as bottle-fed infants (4.4 and 5.7 percent, respectively) [<a href="#rid74">74</a>]. Similar findings have been reported in smaller but prospective studies in Japan [<a href="#rid75">75</a>] and Jamaica [<a href="#rid76">76</a>].</p><p>Another important risk factor is the provirus load in breast milk. This was illustrated in a report from Jamaica in which the risk of transmission ranged from 4.7 to 28.7 per 1000 person months at low and high provirus loads, respectively [<a href="#rid77">77</a>].</p><p>It is likely that the presence of maternal antibodies transferred in utero is protective for some months after birth. A prospective study of breast-fed infants born to seropositive mothers showed that infants seropositive at two years of age remained seropositive (for at least 10 years), but for infants who were seronegative at 2 years, no further transmission was seen [<a href="#rid78">78</a>]. These results suggested that after the period of breastfeeding, the risks of transmission were small prior to puberty.</p><p>Animal models have demonstrated the effectiveness of virus-specific immunoglobulin given prophylactically to prevent HTLV-I transmission [<a href="#rid79">79,80</a>]. Similar studies have not been performed in humans. Freeze-thawing of breast milk is an effective way to reduce transmission [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Bottle-fed infants</span><span class="headingEndMark"> — </span>Since 3 to 4 percent of bottle-fed infants born to HTLV-I infected mothers are HTLV-I seropositive [<a href="#rid74">74</a>], transmission to children by routes other than breast feeding is possible. The period of risk appears to be greatest within the first two years of life. A prospective study of 154 bottle-fed infants born to seropositive mothers showed that the risk of infection was 0.6 percent at one year and 4.6 percent at two years, with no new acquisition of infection for the 10 years following this two-year period [<a href="#rid81">81</a>].</p><p>The route of this transmission remains uncertain. HTLV-I provirus can be identified in cord blood and maternal saliva, but convincing evidence that either of these account for infection in the absence of breast feeding is lacking. In a prospective study, all seven children found to have HTLV-I proviral DNA in cord blood were HTLV-I seronegative at one to two years [<a href="#rid82">82</a>]. One reason for this may be that cord blood provirus is frequently defective and unable to establish infection [<a href="#rid83">83</a>]. Saliva and mouthwash specimens have also been shown to harbor proviral DNA [<a href="#rid84">84-86</a>]. However, lymphocytes are infrequent in saliva, and saliva itself frequently contains HTLV-I antibody [<a href="#rid87">87</a>] and can inhibit cell transmission in vitro [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Sexual transmission</span><span class="headingEndMark"> — </span>HTLV-I can be transmitted via sexual intercourse, but the frequency of this means of transmission has been difficult to define. The prevalence of antibodies to HTLV-I in female sex workers differs by location, ranging from 3.2 to 21.8 percent in Kinshasa, Zaire and Callao, Peru, respectively [<a href="#rid89">89,90</a>].</p><p>As mentioned above, male to female transmission is more efficient than the reverse. As an example, the infection rate was considerably higher in the seronegative heterosexual partner when a man was the HTLV-I positive partner compared to a woman (4.9 versus 1.2 per 100 person-years) [<a href="#rid91">91</a>]. The presence of coexisting genital ulceration and cervicitis is associated with an increased risk of transmission [<a href="#rid63">63,90</a>].</p><p>Transmission via sexual intercourse also appears to be related to viral or proviral DNA load [<a href="#rid31">31,92</a>]. In one study, men who transmitted the virus to their heterosexual partners had significantly higher geometric mean viral loads than non-transmitters [<a href="#rid92">92</a>].</p><p>In one study of 2655 Peruvian men who have sex with men (MSM), HTLV-I infection was detected in 1.8 percent of subjects, while HIV infection was detected in 12.4 percent; 7 percent of HIV-infected men had HTLV coinfection [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Blood transfusion</span><span class="headingEndMark"> — </span>Transfusion of infected cells, but not plasma [<a href="#rid88">88</a>], is an efficient means of HTLV-I transmission. The estimated probability of seroconversion by this route is 40 to 60 percent [<a href="#rid94">94-96</a>], with the time to seroconversion reported as 21 to 47 days [<a href="#rid95">95</a>] with a median of 51 days [<a href="#rid96">96</a>]. The risk of transmission decreases the longer blood is stored [<a href="#rid95">95,96</a>]. For countries with high HTLV-I seroprevalence rates, routine screening of blood donations for this virus is an effective way of reducing transfusion-related infection [<a href="#rid97">97</a>]. However, those countries that would most benefit from screening are often the least able to resource it. (See  <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing"</a>.)</p><p>The seroprevalence of HTLV-I in blood donors is generally much lower than in the general population (5.1 per 100,000 person years in the United States [<a href="#rid62">62</a>], 32 per 100,000 in Taiwan [<a href="#rid98">98</a>]), since patients at risk of bloodborne disease are usually excluded from donating. Where screening occurs, overall risks of transmission are low [<a href="#rid99">99,100</a>]. Countries that routinely screen all blood products for HTLV-I and -II include the United States, Canada, Brazil, Australia, New Zealand, France, and the United Kingdom [<a href="#rid101">101</a>]. In the United States from 2007 to 2008, the residual risk was determined to be 0.29 cases per 10<sup>6</sup> blood products [<a href="#rid102">102</a>]. </p><p class="headingAnchor" id="H13"><span class="h2">Tissue donation</span><span class="headingEndMark"> — </span>There are few data on the risk of transmission of HTLV-I from transplanted organs, as only rare cases have been reported [<a href="#rid103">103-105</a>]. A survey of 99 patients identified through the Japanese Renal Transplant Registry identified a high rate of transmission among 10 patients who were HTLV-1 seronegative at the time of transplant and received an organ from a seropositive donor; after a median follow-up of 4.5 years, HTLV-1-associated myelopathy/tropical spastic paraparesis was reported in 4 of 10 and seroconversion was reported in 7 of 8 (with those data missing in 2 patients) [<a href="#rid106">106</a>]. No HTLV-1-related disease was identified in 30 HTLV-1-positive recipients who received an HTLV-1-positive transplant. </p><p>A small transplant-related transmission cluster was identified in Germany; it included one liver and two kidney recipients who received their organs from a single donor who was retrospectively discovered to be seropositive for HTLV-I [<a href="#rid104">104</a>]. Two of the three recipients developed a cutaneous lymphoproliferative disease within three years following the transplant, an atypical presentation of HTLV-I-associated disease within an unusually rapid time frame; the lymphoproliferative lesions had high HTLV-I DNA concentrations. One of the recipients did not develop antibodies to HTLV-I for several years despite having high levels of HTLV-I DNA in the peripheral blood mononuclear cells. This report suggests the possibility that HTLV-I transmitted to transplant recipients may be associated with an unusual clinical presentation as well as delayed seroconversion and thus be difficult to detect.</p><p>In the United States, organ donations are evaluated for HTLV-I/II. The likelihood of tissue donors having viremia due to HTLV-I/II (as well as hepatitis B, hepatitis C, and HIV) was evaluated in 11,391 tissue donors to five tissue banks in the United States [<a href="#rid107">107</a>]. The estimated probability of HTLV-I/II viremia at the time of donation that would be undetected by screening with current serologic methods was 1 in 128,000 for HTLV-I/II.</p><p class="headingAnchor" id="H14"><span class="h2">Injection drug use</span><span class="headingEndMark"> — </span>The impact of injection drug use (IDU) as a route of transmission varies widely among countries and is dependent upon the baseline seroprevalence in the region. Certain areas (eg, Italy [<a href="#rid108">108</a>], Eastern Europe [<a href="#rid109">109</a>], Thailand [<a href="#rid110">110</a>]) have low seroprevalences among drug users. Higher rates have been reported in areas with a high seroprevalence in the general population (eg, 20 to 40 percent in one Brazilian study [<a href="#rid111">111</a>]). Many studies fail to distinguish between HTLV-I and HTLV-II infection, although those that do suggest that HTLV-I is consistently less prevalent than HTLV-II among IDUs in Western Europe and the United States.</p><p class="headingAnchor" id="H630396321"><span class="h2">Occupational exposure</span><span class="headingEndMark"> — </span>There is a potential risk of HTLV-I transmission following occupational exposure to infected blood through needlestick injury or mucosal splash. However, occupational acquisition has only very rarely been described, and the risk of transmission has never been accurately quantified. In a retrospective study from Australia, 53 health care workers were exposed to HTLV-I-infected blood and received serologic follow-up, and none demonstrated evidence of seroconversion [<a href="#rid112">112</a>]. Reassurance with serological follow-up alone appears reasonable for most occupational HTLV-I exposures, particularly in the absence of any proven, effective postexposure intervention.</p><p class="headingAnchor" id="H438662320"><span class="h2">Zoonotic transmission</span><span class="headingEndMark"> — </span>HTLV-I is thought to have originated from a simian T lymphotrophic virus that was transmitted from a nonhuman primate to man. In Central Africa, where HTLV-I is endemic and close contact with nonhuman primates still occurs, particularly among hunters, zoonotic transmission may be another source of new infections [<a href="#rid113">113,114</a>]. As an example, in a cohort study of 269 individuals who had been bitten by nonhuman primates, the prevalence of HTLV-I was higher than that of controls matched for age, sex, and ethnicity [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H29033435"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Human T-lymphotropic virus (HTLV-I) is estimated to infect 5 to 10 million people worldwide. This virus is the causative agent of two typically fatal diseases: adult T cell leukemia-lymphoma and HTLV-I-associated myelopathy, which is also known as tropical spastic paraparesis. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower levels of viral DNA within peripheral blood mononuclear cells (PBMCs) correlate with asymptomatic infection while higher levels correlate with HTLV-associated diseases, such as HTLV-I-associated myelopathy. (See <a class="local">'Proviral load determination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Like human immunodeficiency virus type 1 (HIV-1), HTLV-I infects CD4 T-cells; however, unlike HIV-1, which causes T-cell death, HTLV-I leads to cellular proliferation and transformation and disease states such as adult T cell leukemia-lymphoma. These two viruses also differ in viral replication rates and genetic stability; HIV is associated with high levels of viremia and genetic heterogeneity, while HTLV-I is associated with a low replication rate and genetic stability of its viral progeny. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HTLV-I is primarily transmitted by breast feeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs. Measures to reduce the risk of transmission exist for each of these routes. (See <a class="local">'Epidemiology and transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of tissue donors having viremia due to HTLV-I is low in the United States. (See <a class="local">'Tissue donation'</a> above.)</p><p></p><p class="headingAnchor" id="H216403057"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David T Scadden, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415.</a></li><li><a class="nounderline abstract_t">de Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9:381.</a></li><li><a class="nounderline abstract_t">Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 2012; 3:388.</a></li><li><a class="nounderline abstract_t">Tagaya Y, Gallo RC. The Exceptional Oncogenicity of HTLV-1. Front Microbiol 2017; 8:1425.</a></li><li><a class="nounderline abstract_t">Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981; 78:6476.</a></li><li><a class="nounderline abstract_t">Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481.</a></li><li><a class="nounderline abstract_t">Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982; 79:2031.</a></li><li><a class="nounderline abstract_t">Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031.</a></li><li><a class="nounderline abstract_t">Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407.</a></li><li><a class="nounderline abstract_t">Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009; 57:161.</a></li><li><a class="nounderline abstract_t">Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci U S A 1983; 80:3618.</a></li><li><a class="nounderline abstract_t">Gaudray G, Gachon F, Basbous J, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76:12813.</a></li><li><a class="nounderline abstract_t">Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713.</a></li><li><a class="nounderline abstract_t">Ghez D, Lepelletier Y, Lambert S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol 2006; 80:6844.</a></li><li><a class="nounderline abstract_t">Jones KS, Petrow-Sadowski C, Huang YK, et al. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008; 14:429.</a></li><li><a class="nounderline abstract_t">Coskun AK, Sutton RE. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J Virol 2005; 79:4150.</a></li><li><a class="nounderline abstract_t">Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003; 115:449.</a></li><li><a class="nounderline abstract_t">Takenouchi N, Jones KS, Lisinski I, et al. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J Virol 2007; 81:1506.</a></li><li><a class="nounderline abstract_t">Hieshima K, Nagakubo D, Nakayama T, et al. Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. J Immunol 2008; 180:931.</a></li><li><a class="nounderline abstract_t">Bangham CRM, Matsuoka M. Human T-cell leukaemia virus type 1: parasitism and pathogenesis. Philos Trans R Soc Lond B Biol Sci 2017; 372.</a></li><li><a class="nounderline abstract_t">Kakuda K, Ikematsu H, Chong WL, et al. Molecular epidemiology of human T lymphotropic virus type 1 transmission in Okinawa, Japan. Am J Trop Med Hyg 2002; 66:404.</a></li><li><a class="nounderline abstract_t">Felber BK, Paskalis H, Kleinman-Ewing C, et al. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 1985; 229:675.</a></li><li><a class="nounderline abstract_t">Sodroski JG, Rosen CA, Haseltine WA. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 1984; 225:381.</a></li><li><a class="nounderline abstract_t">Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997; 15:15.</a></li><li><a class="nounderline abstract_t">Gillet NA, Malani N, Melamed A, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 2011; 117:3113.</a></li><li><a class="nounderline abstract_t">Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999; 22:92.</a></li><li><a class="nounderline abstract_t">Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int J Cancer 1999; 81:859.</a></li><li><a class="nounderline abstract_t">Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999; 180:1487.</a></li><li><a class="nounderline abstract_t">Kwaan N, Lee TH, Chafets DM, et al. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. J Infect Dis 2006; 194:1557.</a></li><li><a class="nounderline abstract_t">Fuchi N, Miura K, Tsukiyama T, et al. Natural Course of Human T-Cell Leukemia Virus Type 1 Proviral DNA Levels in Carriers During Pregnancy. J Infect Dis 2018; 217:1383.</a></li><li><a class="nounderline abstract_t">Iga M, Okayama A, Stuver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis 2002; 185:691.</a></li><li><a class="nounderline abstract_t">Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000; 165:7278.</a></li><li><a class="nounderline abstract_t">Grassmann R, Dengler C, Müller-Fleckenstein I, et al. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A 1989; 86:3351.</a></li><li><a class="nounderline abstract_t">Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992; 66:4570.</a></li><li><a class="nounderline abstract_t">Smith MR, Greene WC. Type I human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway. J Clin Invest 1991; 88:1038.</a></li><li><a class="nounderline abstract_t">Tanaka A, Takahashi C, Yamaoka S, et al. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci U S A 1990; 87:1071.</a></li><li><a class="nounderline abstract_t">Seiki M, Eddy R, Shows TB, Yoshida M. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 1984; 309:640.</a></li><li><a class="nounderline abstract_t">Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19:475.</a></li><li><a class="nounderline abstract_t">Jeang KT, Widen SG, Semmes OJ 4th, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247:1082.</a></li><li><a class="nounderline abstract_t">Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998; 93:81.</a></li><li><a class="nounderline abstract_t">Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006; 103:720.</a></li><li><a class="nounderline abstract_t">Zhao T, Yasunaga J, Satou Y, et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009; 113:2755.</a></li><li><a class="nounderline abstract_t">Arnold J, Zimmerman B, Li M, et al. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 2008; 112:3788.</a></li><li><a class="nounderline abstract_t">Manns A, Murphy EL, Wilks R, et al. Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood 1991; 77:896.</a></li><li><a class="nounderline abstract_t">Kira J, Koyanagi Y, Yamada T, et al. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991; 29:194.</a></li><li><a class="nounderline abstract_t">Kamihira S, Toriya K, Amagasaki T, et al. Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection. Jpn J Cancer Res 1989; 80:1066.</a></li><li><a class="nounderline abstract_t">Kannagi M, Harada S, Maruyama I, et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol 1991; 3:761.</a></li><li><a class="nounderline abstract_t">Parker CE, Nightingale S, Taylor GP, et al. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol 1994; 68:2860.</a></li><li><a class="nounderline abstract_t">Niewiesk S, Daenke S, Parker CE, et al. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol 1995; 69:2649.</a></li><li><a class="nounderline abstract_t">Jacobson S, Reuben JS, Streilein RD, Palker TJ. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. J Immunol 1991; 146:1155.</a></li><li><a class="nounderline abstract_t">Arnulf B, Thorel M, Poirot Y, et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004; 18:126.</a></li><li><a class="nounderline abstract_t">Wodarz D, Hall SE, Usuku K, et al. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc Biol Sci 2001; 268:1215.</a></li><li><a class="nounderline abstract_t">Sabouri AH, Usuku K, Hayashi D, et al. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood 2008; 112:2411.</a></li><li><a class="nounderline abstract_t">Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 2014; 124:3431.</a></li><li><a class="nounderline abstract_t">Yamano Y, Coler-Reilly A. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP. J Neuroimmunol 2017; 304:51.</a></li><li><a class="nounderline abstract_t">Sato T, Coler-Reilly ALG, Yagishita N, et al. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. N Engl J Med 2018; 378:529.</a></li><li><a class="nounderline abstract_t">Fox JM, Mutalima N, Molyneux E, et al. Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa. Trop Med Int Health 2016; 21:312.</a></li><li><a class="nounderline abstract_t">Blattner WA, Saxinger C, Riedel D, et al. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990; 3:1102.</a></li><li><a class="nounderline abstract_t">Mueller N, Okayama A, Stuver S, Tachibana N. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl 1:S2.</a></li><li><a class="nounderline abstract_t">Murphy EL, Watanabe K, Nass CC, et al. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180:1777.</a></li><li><a class="nounderline abstract_t">Taylor GP, Bodéus M, Courtois F, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr 2005; 38:104.</a></li><li><a class="nounderline abstract_t">Chang YB, Kaidarova Z, Hindes D, et al. Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009. J Infect Dis 2014; 209:523.</a></li><li><a class="nounderline abstract_t">Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111:555.</a></li><li><a class="nounderline abstract_t">Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999; 353:1951.</a></li><li><a class="nounderline abstract_t">Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66:2288.</a></li><li><a class="nounderline abstract_t">Nerurkar VR, Song KJ, Saitou N, et al. Interfamilial and intrafamilial genomic diversity and molecular phylogeny of human T-cell lymphotropic virus type I from Papua New Guinea and the Solomon Islands. Virology 1993; 196:506.</a></li><li><a class="nounderline abstract_t">Liu HF, Vandamme AM, Kazadi K, et al. Familial transmission and minimal sequence variability of human T-lymphotropic virus type I (HTLV-I) in Zaire. AIDS Res Hum Retroviruses 1994; 10:1135.</a></li><li><a class="nounderline abstract_t">Biggar RJ, Ng J, Kim N, et al. Human leukocyte antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I. J Infect Dis 2006; 193:277.</a></li><li><a class="nounderline abstract_t">Plancoulaine S, Gessain A, Tortevoye P, et al. A major susceptibility locus for HTLV-1 infection in childhood maps to chromosome 6q27. Hum Mol Genet 2006; 15:3306.</a></li><li><a class="nounderline abstract_t">Kinoshita K, Hino S, Amagaski T, et al. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. Gan 1984; 75:103.</a></li><li><a class="nounderline abstract_t">Yamanouchi K, Kinoshita K, Moriuchi R, et al. Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jacchus) as an experimental model for milk-borne transmission. Jpn J Cancer Res 1985; 76:481.</a></li><li><a class="nounderline abstract_t">Hirata M, Hayashi J, Noguchi A, et al. The effects of breastfeeding and presence of antibody to p40tax protein of human T cell lymphotropic virus type-I on mother to child transmission. Int J Epidemiol 1992; 21:989.</a></li><li><a class="nounderline abstract_t">Tsuji Y, Doi H, Yamabe T, et al. Prevention of mother-to-child transmission of human T-lymphotropic virus type-I. Pediatrics 1990; 86:11.</a></li><li><a class="nounderline abstract_t">Takahashi K, Takezaki T, Oki T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group. Int J Cancer 1991; 49:673.</a></li><li><a class="nounderline abstract_t">Takezaki T, Tajima K, Ito M, et al. Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group. Leukemia 1997; 11 Suppl 3:60.</a></li><li><a class="nounderline abstract_t">Wiktor SZ, Pate EJ, Rosenberg PS, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol 1997; 1:37.</a></li><li><a class="nounderline abstract_t">Li HC, Biggar RJ, Miley WJ, et al. Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I. J Infect Dis 2004; 190:1275.</a></li><li><a class="nounderline abstract_t">Ando Y, Kakimoto K, Tanigawa T, et al. Effect of freeze-thawing breast milk on vertical HTLV-I transmission from seropositive mothers to children. Jpn J Cancer Res 1989; 80:405.</a></li><li><a class="nounderline abstract_t">Miyoshi I, Takehara N, Sawada T, et al. Immunoglobulin prophylaxis against HTLV-I in a rabbit model. Leukemia 1992; 6 Suppl 1:24.</a></li><li><a class="nounderline abstract_t">Sawada T, Iwahara Y, Ishii K, et al. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J Infect Dis 1991; 164:1193.</a></li><li><a class="nounderline abstract_t">Ando Y, Matsumoto Y, Nakano S, et al. Long-term follow-up study of HTLV-I infection in bottle-fed children born to seropositive mothers. J Infect 2003; 46:9.</a></li><li><a class="nounderline abstract_t">Katamine S, Moriuchi R, Yamamoto T, et al. HTLV-I proviral DNA in umbilical cord blood of babies born to carrier mothers. Lancet 1994; 343:1326.</a></li><li><a class="nounderline abstract_t">Kazi A, Miyata H, Kamahora T, et al. Deleted HTLV-1 provirus in cord-blood samples of babies born to HTLV-1-carrier mothers. Int J Cancer 1998; 77:701.</a></li><li><a class="nounderline abstract_t">Achiron A, Pinhas-Hamiel O, Barak Y, et al. Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers. Arch Virol 1996; 141:147.</a></li><li><a class="nounderline abstract_t">Achiron A, Higuchi I, Takenouchi N, et al. Detection of HTLV type I provirus by in situ polymerase chain reaction in mouthwash mononuclear cells of HAM/TSP patients and HTLV type I carriers. AIDS Res Hum Retroviruses 1997; 13:1067.</a></li><li><a class="nounderline abstract_t">Miyoshi I, Sawada T, Iwahara Y, et al. Excretion of HTLV-I in saliva. JAMA 1992; 267:236.</a></li><li><a class="nounderline abstract_t">Archibald D, Essex M, McLane MF, et al. Antibodies to HTLV-1 in saliva of seropositive individuals from Japan. Viral Immunol 1987-1988; 1:241.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Terada K, Nishida N, et al. Inhibitory activity in saliva of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro: evaluation of saliva as an alternative source of transmission. J Clin Microbiol 1995; 33:1510.</a></li><li><a class="nounderline abstract_t">Wignall FS, Hyams KC, Phillips IA, et al. Sexual transmission of human T-lymphotropic virus type I in Peruvian prostitutes. J Med Virol 1992; 38:44.</a></li><li><a class="nounderline abstract_t">Zunt JR, Dezzutti CS, Montano SM, et al. Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis. J Infect Dis 2002; 186:1669.</a></li><li><a class="nounderline abstract_t">Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis 1993; 167:57.</a></li><li><a class="nounderline abstract_t">Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:193.</a></li><li><a class="nounderline abstract_t">La Rosa AM, Zunt JR, Peinado J, et al. Retroviral infection in Peruvian men who have sex with men. Clin Infect Dis 2009; 49:112.</a></li><li><a class="nounderline abstract_t">Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989; 74:388.</a></li><li><a class="nounderline abstract_t">Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46:245.</a></li><li><a class="nounderline abstract_t">Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51:886.</a></li><li><a class="nounderline abstract_t">Kamihira S, Nakasima S, Oyakawa Y, et al. Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors. Vox Sang 1987; 52:43.</a></li><li><a class="nounderline abstract_t">Lu SC, Kao CL, Chin LT, et al. Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999. Int J Hematol 2001; 74:333.</a></li><li><a class="nounderline abstract_t">Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003; 169:767.</a></li><li><a class="nounderline abstract_t">Pillonel J, Laperche S, Saura C, et al. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002; 42:980.</a></li><li><a class="nounderline abstract_t">Murphy EL. Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety. Transfus Clin Biol 2016; 23:13.</a></li><li><a class="nounderline abstract_t">Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev 2012; 26:119.</a></li><li><a class="nounderline abstract_t">Armstrong MJ, Corbett C, Rowe IA, et al. HTLV-1 in solid-organ transplantation: current challenges and future management strategies. Transplantation 2012; 94:1075.</a></li><li><a class="nounderline abstract_t">Glowacka I, Korn K, Potthoff SA, et al. Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor. Clin Infect Dis 2013; 57:1417.</a></li><li><a class="nounderline abstract_t">Toro C, Rodés B, Poveda E, Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003; 75:102.</a></li><li><a class="nounderline abstract_t">Yamauchi J, Yamano Y, Yuzawa K. Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation. N Engl J Med 2019; 380:296.</a></li><li><a class="nounderline abstract_t">Zou S, Dodd RY, Stramer SL, et al. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351:751.</a></li><li><a class="nounderline abstract_t">Giuliani M, Rezza G, Lepri AC, et al. Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases. Sex Transm Dis 2000; 27:87.</a></li><li><a class="nounderline abstract_t">Poljak M, Bednarik J, Rednak K, et al. Seroprevalence of human T cell leukaemia/lymphoma virus type I (HTLV-I) in pregnant women, patients attending venereological outpatient services and intravenous drug users from Slovenia. Folia Biol (Praha) 1998; 44:23.</a></li><li><a class="nounderline abstract_t">Urwijitaroon Y, Barusrux S, Puapairoj C, et al. Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance. J Med Assoc Thai 1997; 80 Suppl 1:S102.</a></li><li><a class="nounderline abstract_t">Dourado I, Andrade T, Carpenter CL, Galvão-Castro B. Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz 1999; 94:13.</a></li><li><a class="nounderline abstract_t">Hewagama S, Krishnaswamy S, King L, et al. Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in central Australia, 2002-2012. Clin Infect Dis 2014; 59:85.</a></li><li><a class="nounderline abstract_t">Filippone C, Betsem E, Tortevoye P, et al. A Severe Bite From a Nonhuman Primate Is a Major Risk Factor for HTLV-1 Infection in Hunters From Central Africa. Clin Infect Dis 2015; 60:1667.</a></li><li><a class="nounderline abstract_t">Kazanji M, Mouinga-Ondémé A, Lekana-Douki-Etenna S, et al. Origin of HTLV-1 in hunters of nonhuman primates in Central Africa. J Infect Dis 2015; 211:361.</a></li></ol></div><div id="topicVersionRevision">Topic 8316 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6261256" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318266" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An HTLV-I vaccine: why, how, for whom?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23162541" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiological Aspects and World Distribution of HTLV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28824561" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Exceptional Oncogenicity of HTLV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7031654" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301762" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adult T-cell leukemia: clinical and hematologic features of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979048" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2871307" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : HTLV-I associated myelopathy, a new clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2863442" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456423" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6304725" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438606" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12589003" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809290" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376405" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767416" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14622599" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108050" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178833" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893939" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human T-cell leukaemia virus type 1: parasitism and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164296" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular epidemiology of human T lymphotropic virus type 1 transmission in Okinawa, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2992082" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6330891" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9143680" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human T cell leukemia virus type I (HTLV-I) and human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228324" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534152" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prospective study of HTLV-I infection in an initially asymptomatic cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362130" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10515807" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083040" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346571" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Natural Course of Human T-Cell Leukemia Virus Type 1 Proviral DNA Levels in Carriers During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11120862" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2541443" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1351105" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832173" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Type I human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2300570" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6328324" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244044" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multiple viral strategies of HTLV-1 for dysregulation of cell growth control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2309119" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9546394" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407133" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064727" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689544" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1993227" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012389" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2514169" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1911545" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512153" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7533860" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1704032" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574331" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410146" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502825" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24960164" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542993" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells that produces an inflammatory positive feedback loop via astrocytes in HAM/TSP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29414279" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26700941" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Seroprevalence of HTLV-1 and HTLV-2 amongst mothers and children in Malawi within the context of a systematic review and meta-analysis of HTLV seroprevalence in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213511" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A study of HTLV-I and its associated risk factors in Trinidad and Tobago.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797696" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Findings from the Miyazaki Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10558931" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608533" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24068702" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2789009" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sexual transmission of human T-lymphotropic virus type I (HTLV-I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371587" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Human T-lymphotropic virus type I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548762" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372432" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Interfamilial and intrafamilial genomic diversity and molecular phylogeny of human T-cell lymphotropic virus type I from Papua New Guinea and the Solomon Islands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7826698" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Familial transmission and minimal sequence variability of human T-lymphotropic virus type I (HTLV-I) in Zaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16362892" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Human leukocyte antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028113" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A major susceptibility locus for HTLV-1 infection in childhood maps to chromosome 6q27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6329875" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2991061" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jacchus) as an experimental model for milk-borne transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468864" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The effects of breastfeeding and presence of antibody to p40tax protein of human T cell lymphotropic virus type-I on mother to child transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359666" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Prevention of mother-to-child transmission of human T-lymphotropic virus type-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1937953" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9209298" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195229" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15346338" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2502514" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of freeze-thawing breast milk on vertical HTLV-I transmission from seropositive mothers to children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1347800" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Immunoglobulin prophylaxis against HTLV-I in a rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955718" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504602" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term follow-up study of HTLV-I infection in bottle-fed children born to seropositive mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910326" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HTLV-I proviral DNA in umbilical cord blood of babies born to carrier mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9688302" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Deleted HTLV-1 provirus in cord-blood samples of babies born to HTLV-1-carrier mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629942" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264294" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Detection of HTLV type I provirus by in situ polymerase chain reaction in mouthwash mononuclear cells of HAM/TSP patients and HTLV type I carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727518" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Excretion of HTLV-I in saliva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3509678" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Antibodies to HTLV-1 in saliva of seropositive individuals from Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7650176" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Inhibitory activity in saliva of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro: evaluation of saliva as an alternative source of transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1402830" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sexual transmission of human T-lymphotropic virus type I in Peruvian prostitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12447745" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418183" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8680892" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480577" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Retroviral infection in Peruvian men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2752118" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6328765" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1639536" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2885977" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11721972" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557314" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12385407" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26778839" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21871776" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23060278" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : HTLV-1 in solid-organ transplantation: current challenges and future management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23956168" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Delayed seroconversion and rapid onset of lymphoproliferative disease after transmission of human T-cell lymphotropic virus type 1 from a multiorgan donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12544880" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30650320" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317888" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676975" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10730871" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Seroprevalence of human T cell leukaemia/lymphoma virus type I (HTLV-I) in pregnant women, patients attending venereological outpatient services and intravenous drug users from Slovenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347655" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029907" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729501" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in central Australia, 2002-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25722199" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A Severe Bite From a Nonhuman Primate Is a Major Risk Factor for HTLV-1 Infection in Hunters From Central Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147276" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Origin of HTLV-1 in hunters of nonhuman primates in Central Africa.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
